Development of an epitope panel for consistent identification of antigen‐specific T‐cells in humans

Abstract

We aimed to establish a panel of MHC-peptide multimers suitable as a positive control in the detection of HLA A*0201 restricted antigen specific T cells (ASTC) by flow cytometry. MHC Dextramers were loaded with HLA A*0201 binding peptides from viral antigens and melanoma targets identified from a literature search and in silico prediction. Peripheral blood mononuclear cells (PBMC) from healthy donors were analysed with the MHC Dextramers using flow cytometry. The best performing epitopes were tested on PBMC from patients undergoing testing for Mycobacterium tuberculosis infection to assess the coverage of this epitope panel. Of 21 candidate epitopes, ASTC could be detected against 12 (57·1%) in at least one of 18 healthy blood donors. Reactivity to two or more epitopes was seen in 17 of the 18 donors (94·4%). We selected the six best-performing epitopes and demonstrated a positive response in 42 (97·7%) of 43 patient samples (healthy, latent and active M. tuberculosis infection). The selected panel of six antigenic epitopes sufficed as a positive control in the detection of ASTC in HLA A*0201. Performance was robust in different stages of latent and active M. tuberculosis infection, indicating reliability also during infection.

Advances in Proteomic Techniques for Cytokine Analysis: Focus on Melanoma Research

“…The degree of T-cell infiltration and T-cell phenotype in the tumour are important predictors of response of patients to cancer immunotherapy [ 46 ]. An effort is applied to the search for melanoma antigen-specific cytotoxic T-cells that could be used in therapy [ 47 ]. Adoptive cell therapy with tumour infiltrating T-lymphocytes, isolated from patient’s tumour, in vitro expanded and applied via infusion, is already showing positive outcomes as an effective treatment for metastatic melanoma [ 48 ].…”